News tagged with gleevec
Protein that drives survival of gastrointestinal tumors identified
(PhysOrg.com) -- For patients with gastrointestinal stromal tumors, or GISTs, the blockbuster cancer drug Gleevec has been a reason to hope. Since the drug’s introduction, survival rates have climbed ...
Dec 23, 2010 |
4.7 / 5 (3) |
0
|
A lethal cancer knocked down by one-two drug punch
In the battle against cancer, allies can come from unexpected sources. Research at The Jackson Laboratory has yielded a new approach to treating leukemia, one that targets leukemia-proliferating cells with drugs that are ...
Jun 07, 2009 |
5 / 5 (4) |
2
Cancer drug shows promise for treating scleroderma
A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated ...
Mar 28, 2011 |
5 / 5 (2) |
0
CML patients on imatinib have similar mortality rates to general population
Patients taking imatinib (Gleevec) for CML, or chronic myelogenous leukemia, and in remission after two years of treatment, have a mortality rate similar to that of the general population according to a study published online ...
Mar 22, 2011 |
not rated yet |
0
'Smart drug' targets new mutation, dramatically shrinks aggressive sarcoma and lung cancer
A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the ...
Oct 27, 2010 |
5 / 5 (1) |
0
Researchers say vaccine appears to 'mop up' leukemia cells Gleevec leaves behind
Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) ...
Jan 07, 2010 |
not rated yet |
0
Drug could provide first treatment for scleroderma
Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment ...
Oct 18, 2009 |
5 / 5 (2) |
1
Finding key to cancer drug Gleevec's limitations
University of Michigan researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not ...
Aug 05, 2009 |
not rated yet |
1
Scientists find new structural motif in key enzymes is essential to prevent autoimmune disease
Scientists from the Scripps Research Institute and the Genomics Institute of the Novartis Research Foundation have found a specific mutation that leads to the development of severe autoimmune kidney disease in mice. The research ...
Medicine & Health / Medical research
Jan 16, 2009 |
not rated yet |
0
Second-line CML drugs evoke faster response than front-line therapy
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University ...
Dec 07, 2009 |
not rated yet |
0
Predicting patient response to gleevec in gastrointestinal stromal tumors
Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings ...
Apr 21, 2009 |
not rated yet |
0
Imatinib
Imatinib (originally STI571) is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia/Latin America) as its mesylate salt, imatinib mesilate (INN). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and some other diseases. By 2011, Gleevec has been FDA approved to treat ten different cancers. In CML, the tyrosine kinase enzyme ABL is locked in its activated form. It induces the abnormal phenotypes of CML: excessive proliferation and high white blood cell count. Imatinib binds to the site of tyrosine kinase activity, and prevents its activity, thereby causing tumor cell apoptosis.
Imatinib is the first member of a new class of agents that act by specifically inhibiting a certain enzyme that is characteristic of a particular cancer cell, rather than non-specifically inhibiting and killing all rapidly dividing cells, and served as a model for other targeted therapy modalities through tyrosine kinase inhibition.
For more information about Imatinib, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
